With the increasing use of CDK4/6 inhibitors, more prospective studies are needed to confirm the effect of PR status and first-line POD24 on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitors combined with endocrine as first-line therapy. This evidence concerns the gene ERBB2 and breast cancer.